-+ 0.00%
-+ 0.00%
-+ 0.00%

Fennec says four PEDMARK studies accepted for presentation at ASCO annual meeting

PUBT·04/21/2026 20:32:56
Listen to the news
Fennec says four PEDMARK studies accepted for presentation at ASCO annual meeting
  • Fennec Pharmaceuticals reported four PEDMARK (sodium thiosulfate) studies accepted for presentation at 2026 ASCO Annual Meeting in Chicago on May 29–June 2.
  • Two studies will be presented as posters, including Japanese pediatric data on delayed sodium thiosulfate use to reduce cisplatin-related hearing loss.
  • Two additional analyses will be published as abstracts only, focusing on real-world use in young adults plus adult head and neck cancer hearing outcomes.
  • Full abstracts will be released on May 21, 2026, ahead of the meeting.
  • Update underscores expanding clinical interest beyond PEDMARK’s current US pediatric label, supporting longer-term potential for broader adoption.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211630PRIMZONEFULLFEED9694223) on April 21, 2026, and is solely responsible for the information contained therein.